Healthcare Most Volatile: XOMA Corp (NASDAQ:XOMA), Keryx Biopharmaceuticals (NASDAQ:KERX), Rexahn Pharmaceuticals (NYSEMKT:RNN), IsoRay (NYSEMKT:ISR)

The XOMA Corp (NASDAQ:XOMA) on Mar. 4 announced 2013 operational highlights and financial results for the fourth quarter and year ended December 31, 2013. The company recorded total revenues of $35.5 million for the twelve months ended December 31, 2013, compared with $33.8 million during the same period of 2012. For the three months ended December 31, 2013, XOMA recorded revenues of $12.5 million compared to $7.4 million during the corresponding period of 2012. For the year ended December 31, 2013, XOMA had a net loss of $124.1 million, or $1.43 per share, compared with a net loss of $71.1 million, or $1.10 per share, in the year ended December 31, 2012. XOMA Corp (NASDAQ:XOMA) shares after opening at $6.04 moved to $6.05 on last trade day and at the end of the day closed at $5.41. Company price to sales ratio in past twelve months was calculated as 11.4214.48 and price to cash ratio as 4.23. XOMA Corp (NASDAQ:XOMA) showed a negative weekly performance of -9.08%.

The Keryx Biopharmaceuticals (NASDAQ:KERX) on Jan. 21 announced that it has commenced a $90 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund pre-launch/launch inventory build-up and pre-commercial/commercial activities related to Zerenex, the ongoing development of Zerenex in pre-dialysis, and other general corporate purposes. Keryx Biopharmaceuticals (NASDAQ:KERX) shares fell -4.92% in last trading session and ended the day on $14.11. KERX return on equity ratio is recorded as -71.80% and its return on assets is -59.80%.Keryx Biopharmaceuticals (NASDAQ:KERX) yearly performance is 99.58%.

The Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) on Mar. 10 announced initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors. The study is still ongoing and the maximal tolerated dose has not yet been achieved. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares moved down -0.77% in last trading session and was closed at $1.29, while trading in range of $1.18-$1.33.Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) year to date performance is 152.94%.

The IsoRay, Inc. (NYSEMKT:ISR) on Mar. 19 announced another milestone – the treatment of a pediatric patient’s tumor utilizing multiple Cesium-131 sutured seed meshes for internal radiation therapy. Dr. Anthony Crimaldi at Levine Cancer Institute, Charlotte, NC, successfully completed the world’s first pediatric implant using IsoRay Medical’s Cesium-131 brachytherapy mesh. Dr. Crimaldi said “The patient was a 12 year old male who was diagnosed with recurrent metastatic Wilms tumor in the pleural space of the lower aspect of his left chest. Prior to this he had been treated extensively, but nevertheless the cancer returned. IsoRay, Inc. (NYSEMKT:ISR) weekly performance is 109.73%. On last trading day company shares ended up $2.37. IsoRay, Inc. (NYSEMKT:ISR) distance from 50-day simple moving average is 158.51%. Analysts mean target price for the company is $1.50.